Case Report

Chondroid Chordoma in an Atypical Location

Iñigo Royo Crespo,a,† Juan José Rivas de Andrés,a Raúl Embún Flor,a Severiano Cortés Francob

a Servicio de Cirugía Torácica, Hospital Universitario Miguel Servet y Hospital Clínico Universitario Lozano Blesa, Zaragoza, Spain

b Servicio de Neurocirugía, Hospital Universitario Miguel Servet, Zaragoza, Spain

ABSTRACT

Chordoid chordoma is an extremely rare tumour with an annual incidence of around 0.1 cases per 100,000 population. Involvement of the thoracic vertebrae may be present in 2%–5% of cases.

Definitive diagnosis usually requires a suitable distinction between this and other mesenchymal tumours such as chondrosarcomas, so immunohistochemical analysis is virtually mandatory.

In spite of its slow-growing nature, chondroid chordoma tends to relapse, and it may eventually become malignant, often jeopardising the patient’s prognosis. Although surgery remains the main therapeutic approach, research into the molecular and genetic aspects of this tumour is ongoing. These new advances are likely to improve future oncology therapies by complementing surgery and radiotherapy, changing the currently poor prognosis.

We report the case of a patient with a chondroid chordoma involving the thoracic vertebrae and pleural cavity, and the treatment performed.

© 2012 SEPAR. Published by Elsevier España, S.L. All rights reserved.

Cordoma condroide de localización atípica

Resumen

El cordoma condroide de localización vertebral torácica es un tipo de tumor que constituye una auténtica rareza. La incidencia anual del cordoma condroide se cifra en 0.1/100,000 habitantes, y la afectación torácica se aprecia en el 2% al 5% de los casos.

Su diagnóstico definitivo se ve complicado por su semejanza con otros tumores como los condrosarcomas, por lo que es preciso acudir al estudio inmunohistoquímico.

Su capacidad de recidiva y la tendencia a la malignización a pesar de su naturaleza de lento crecimiento provocan que su tratamiento, predominantemente quirúrgico, sea de una complejidad nada desestimable.

Su comportamiento evolutivo tan agresivo está siendo motivo de estudio a nivel molecular y genético para la elaboración de nuevas terapias oncológicas médicas con el fin de complementar la cirugía y la radioterapia, cuando estén sean aplicables.

Se presenta un caso de localización torácica vertebral e intrapleural, así como el tratamiento practicado.

© 2012 SEPAR. Publicado por Elsevier España, S.L. Todos los derechos reservados.

Introduction

Chordoma is a slow-growing malignant tumour originating from remnants of the notochord. It accounts for 1%–4% of malignant primary bone tumours, 50% of which are located in the sacrococcygeal region. Its annual incidence is 0.1/100,000 population, and thoracic involvement may be observed in 2%–5% of cases.

It is the only neoplasm of embryogenic origin that presents in the later decades of life. In the case of the vertebrae, it usually appears in young individuals and is much more aggressive. It occurs predominantly in males (2.7:1−1.6:1). Chordomas have a great capacity for recurrence and malignant transformation, despite their slow-growing nature.

Clinical Observation

A 52-year-old man, with no medical history of interest, presented with a 6-month history of dorsal thoracic pain. As the patient’s symptoms did not improve, it was decided to perform magnetic resonance imaging (MRI), following a normal chest radiograph. The diagnosis was costal hydatidosis with intraspinal...
upper lobe, adding costal resection of the sixth and seventh ribs and their respective intercostal spaces, as well as the fifth intercostal space. Other lesions contiguous with the large tumour were observed, which required extrapleural resection. Curettage of vertebral zone D6–D7 was performed. Once the whole specimen had been resected en bloc, disseminated lesions could be observed in the diaphragmatic and parietal pleura, suspicious of implants that were shown to be secondary to the lesion. The defect was reconstructed using prosthetic material covered by the trapezius muscle. The patient was discharged on the seventh day post-operatively with satisfactory clinical process and no neurological involvement.

Pathological examination revealed the presence of a 12.8 cm × 7.3 cm chondroid chordoma, which respected the underlying skeletal muscle and resected lung parenchyma.

After treatment with adjuvant radiotherapy and EGFR inhibitors, the disease is currently stable and the patient remains free of neurological symptoms.

**Discussion**

The presence of chordomas at the level of the thoracic vertebrae is a rare entity (Table 1). Their main symptom is mechanical pain, but they progress with the onset of neurological symptoms due to their growth.

CT scans are used to characterise the involvement of the vertebral bodies, presence of a paravertebral tumour, and intraspinal and disc space involvement. MRI helps to clarify the epidural extension, spinal cord compression or the presence of epidural metastases. The use of positron emission tomography (PET) or PET-CT, where the chordoma behaves like a lesion with increased glucose uptake, is very discretely referenced in the literature, both for the initial diagnosis and for follow-up.

Depending on its histopathology, it can be classified into: classic, chondroid, undifferentiated, sarcomatoid, intradural and intraspinal (mediastinal).

Its diagnosis is confirmed by cytokeratin-positive staining and expression of the *brachyury* gene. This gene is a specific biomarker that enables differentiation between chordomas and chondrosarcomas, and is the object of gene therapy studies. Other alternatives are being investigated along the same line, such as the use of EGFR inhibitors (erlotinib and combined gefitinib-cetuximab), with promising results.

The ideal treatment is through an aggressive surgical approach, attempting to achieve en bloc resection with the widest free surgical margins possible, otherwise recurrence generally occurs, although this is not always possible given the extension of the lesion and/or structures affected.
Without adequate margins, adjuvant radiotherapy must be administered to try to increase the hypothetical disease-free survival.\textsuperscript{1,2} The local recurrence rate is around 26\%–68\%.\textsuperscript{2} Chordomas can metastasise in 20\%–60\% of cases\textsuperscript{1} (skin, lung, lymphatic system, etc.). The 5-year survival for this tumour is generally between 10\% and 70\%.\textsuperscript{1,2,8}

References